TOFIDENCE

Biological Biogen, Inc.
Total Payments
$5.6M
Transactions
24
Doctors
14
Companies
1

Payment Trends by Year

Year Amount Transactions Doctors
2024 $5.6M 24 14

Payments by Nature

Nature of Payment Amount Transactions Share
Unspecified $5.6M 4 99.8%
Consulting Fee $6,538 7 0.1%
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $1,635 1 0.0%
Food and Beverage $256.35 9 0.0%
Education $187.50 3 0.0%

Payments by Type

Research
$5.6M
4 transactions
General
$8,617
20 transactions

Research Studies & Clinical Trials

Study Name Sponsor Amount Doctors
A Randomized, Double-Blind, Parallel-Group, Phase I Study to Evaluate the Pharmacokinetics, Safety, and Immunogenicity of BIIB800 s.c. compared to the Reference Product Actemra® in Healthy Subjects Biogen, Inc. $5.6M 0

Top Doctors Receiving Payments for TOFIDENCE

Doctor Specialty Location Total Records
Unknown Madison, WI $5.6M 4
, M.D Rheumatology New York, NY $3,742 4
, MD Rheumatology Phoenix, AZ $2,044 2
, M.D Rheumatology New York, NY $1,496 2
, MD Rheumatology Destin, FL $954.00 1
, M.D Rheumatology Dallas, TX $109.96 1
, M.D Specialist San Diego, CA $62.50 1
, D.O Rheumatology Glendale, AZ $62.50 1
, M.D Internal Medicine Beverly Hills, CA $44.12 2
, AGNP Gerontology Casa Grande, AZ $21.53 1
, M.D Obesity Medicine Carlsbad, CA $17.92 1
, APRN Nurse Practitioner Surprise, AZ $16.15 1
Madison Abrams Physician Assistant Surprise, AZ $16.15 1
, MD Rheumatology Mckinney, TX $15.26 1
, M.D Rheumatology Mckinney, TX $15.26 1

About TOFIDENCE

TOFIDENCE is a biological associated with $5.6M in payments to 14 healthcare providers, recorded across 24 transactions in the CMS Open Payments database. The primary manufacturer is Biogen, Inc..

Payment data is available from 2024 to 2024. In 2024, $5.6M was paid across 24 transactions to 14 doctors.

The most common payment nature for TOFIDENCE is "Unspecified" ($5.6M, 99.8% of total).

TOFIDENCE is associated with 1 research study, including "A Randomized, Double-Blind, Parallel-Group, Phase I Study to Evaluate the Pharmacokinetics, Safety, and Immunogenicity of BIIB800 s.c. compared to the Reference Product Actemra® in Healthy Subjects" ($5.6M).